BASF Pharma Solutions has announced a global price increase of up to 20% on pharmaceutical excipients and selected active pharmaceutical ingredients (APIs), citing sustained pressure from rising energy and raw material costs worldwide.
The adjustment, announced yesterday, takes immediate effect or will be applied in line with existing contractual terms.
BASF says that it will continue to monitor market conditions and communicate further changes as required.
Excipients are critical to drug stability, bioavailability and patient safety. APIs provide the therapeutic effect of a medicine.
Both categories sit at the heart of pharmaceutical manufacturing supply chains, making pricing shifts from a major supplier such as BASF a notable development for manufacturers and procurement teams across the industry.
BASF Pharma Solutions is one of the world's leading suppliers of pharmaceutical ingredients, with a broad portfolio spanning cellulose derivatives, polyvinylpyrrolidone (PVP)-based excipients, lipid excipients and selected APIs.
The company frames the price adjustment as necessary to protect long-term supply reliability and product quality — factors of particular concern to drug manufacturers managing tightly regulated production environments.
For pharmaceutical manufacturers, particularly those producing generic medicines with narrower margins, input cost increases of this scale may necessitate a review of formulation sourcing strategies or longer-term supply agreements.
BASF has indicated it will provide ongoing market communications as conditions evolve.